preclinical research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
In RNA synthesis, the 2'-hydroxy group is protected with TBDMS (t-butyldimethylsilyl) group. or with TOM (tri-iso-propylsilyloxymethyl) group, both being removable by treatment with fluoride ion. The phosphite moiety also bears a diisopropylamino (iPr2N) group reactive under acidic conditions. Upon activation, the diisopropylamino group leaves to be substituted by the 5'-hydroxy group of the support-bound oligonucleotide (see "Step 2: Coupling" below).
== External links == CD49a+antigen at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Human ITGA1 genome location and ITGA1 gene details page in the UCSC Genome Browser. ITGA1[link removed] Info with links in the Cell Migration Gateway Archived 2014-12-11 at the Wayback Machine PDBe-KB provides an overview of all the structure information available in the PDB for Human Integrin alpha-1
==== Type 3 ==== VWD type 3 is a rare but the most severe form of VWD. It occurs in individuals who are homozygous for the defective gene, resulting in a severe quantitative deficiency or complete absence of von Willebrand factor (VWF) production. In VWD type 3, VWF is undetectable in the VWF antigen assay. Since VWF normally protects coagulation factor VIII from proteolytic degradation, the total absence of VWF leads to extremely low factor VIII levels (typically 1-10%). These low levels are equivalent to those seen in severe hemophilia A, with clinical manifestations of life-threatening external and internal hemorrhages. The inheritance pattern of VWD type 3 is autosomal recessive, meaning that both parents must carry the defective gene for their child to be affected. In contrast, hemophilia A follows an X-linked recessive inheritance pattern. Additional diagnostic tools for VWD type 3 include assessing VWF activity using the Ristocetin cofactor assay and Collagen binding assay. In VWD type 3, VWF activity is either absent or approaching undetectable. VWF multimer analysis reveals no bands or very faint bands on electrophoresis. Additionally, Ristocetin-Induced Platelet Agglutination (RIPA) is typically absent or severely low.
Natural iron (26Fe) consists of four stable isotopes: 5.85% 54Fe, 91.75% 56Fe, 2.12% 57Fe and 0.28% 58Fe. There are 28 known radioisotopes and 8 nuclear isomers, the most stable of which are 60Fe (half-life 2.62 million years) and 55Fe (half-life 2.7562 years). Much of the past work on measuring the isotopic composition of iron has centered on determining 60Fe variations due to processes accompanying nucleosynthesis (e.g., meteorite studies) and ore formation. In the last decade however, advances in mass spectrometry technology have allowed the detection and quantification of minute, naturally occurring variations in the ratios of the stable isotopes of iron. Much of this work has been driven by the Earth and planetary science communities, though applications to biological and industrial systems are beginning to emerge.
Sources: en.wikipedia.org
==== Agriculture and land ==== Liu Wenhui's agricultural policy put much emphasis on wage laborers working under state-owned enterprises, a marked departure from Zhao Erfeng's more explicitly colonialist model of settlers working on state-owned land. In 1939, the Agriculture Improvement Institute was formed and embarked on a variety of projects across Xikang, including fertilizer plants, ranches, farms, plantations, and sericulture. In addition, the Institute installed weather monitoring stations across the province. Due to a lack of resources, none of these projects were particularly successful, save for perhaps the farm at Taining which was 2.5 million mu in area and remained in existence as of 2021. Although Liu maintained the Zhao-era policy that all wasteland or non-cultivated areas (huang) were state-owned, in practice state farms ended up renting even huang areas from landowners. This was because in the early Republican era, the government began selling deeds to the land in Xikang and charging taxes on the sale of deeds, deriving much profit from it. This state of affairs was not addressed by the Liu administration, perhaps due to the fact that much of the Qing-era uncultivated land was already being utilized. By 1940, income from the deed tax was equivalent to around one-third of that of the land tax.
Peter Thomas DeMarco (March 6, 1932 – October 26, 2005) was an American physician who graduated from Albright College in Pennsylvania and achieved his doctor of medicine degree in 1957 from Hahnemann Medical College of Philadelphia, Pennsylvania. He had a research laboratory and a medical practice in Pine Hill, New Jersey. He treated patients with procaine polyvinylpyrrolidone (PVP), but his medical license was suspended in New Jersey and Pennsylvania for using the unapproved therapy after an experimental permit for Procaine-PVP was withdrawn. The FDA also said his therapy might cause cancer. This was a common misconception in the 1970s. Later research revealed procaine has anti-cancer effects in human cancer cells.
=== Metropolis-coupled MCMC === Metropolis-coupled MCMC algorithm (MC³) has been proposed to solve a practical concern of the Markov chain moving across peaks when the target distribution has multiple local peaks, separated by low valleys, are known to exist in the tree space. This is the case during heuristic tree search under maximum parsimony (MP), maximum likelihood (ML), and minimum evolution (ME) criteria, and the same can be expected for stochastic tree search using MCMC. This problem will result in samples not approximating correctly to the posterior density. The (MC³) improves the mixing of Markov chains in presence of multiple local peaks in the posterior density. It runs multiple (m) chains in parallel, each for n iterations and with different stationary distributions
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.